BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF)
Wednesday announced that it achieved proof of concept in the Phase IIa study of
its lead clinical candidate, Bria-IMT(Trademarked), in advanced breast cancer.
The company followed the after-hours news with a live webcast discussing the
results, as presented by the company’s CEO Dr. Bill Williams.
The data demonstrates promising anti-tumor activity of
Bria-IMT in heavily pre-treated advanced breast cancer patients. BriaCell is
now focusing on the combination study of Bria-IMT with pembrolizumab
(Keytruda®, manufactured by Merck & Co., Inc.) or ipilimumab (Yervoy®,
manufactured by Bristol-Myers Squibb Company) in patients with advanced breast
cancer.
“Bria-IMT appears to be most effective in patients who match
with Bria-IMT at 2 HLA loci (types) further supporting BriaCell’s HLA Matching
Hypothesis, and the development of Bria-OTS to cover 90% of the patient
population. We are delighted with these positive clinical findings that confirm
our HLA Matching Hypothesis in the Phase I/IIa trial in advanced breast cancer
showing significant tumor shrinkage without serious side effects,” Dr. Williams
stated in the press release. “We believe that combination studies with immune
checkpoint inhibitors should create even more potent anti-cancer immune
responses, leading to our strategy of combination studies of Bria-IMT with
Keytruda® or Yervoy®.”
To view the slide presentation, visit http://ibn.fm/X5Hgt
To view the press release, visit http://ibn.fm/QQ442
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company
developing targeted and safe approaches for the management of cancer. BriaCell
is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, its lead
candidate, in a combination study with pembrolizumab [Keytruda®; manufactured
by Merck & Co., Inc.] or ipilimumab [Yervoy®; manufactured by Bristol-Myers
Squibb Company]. The combination study is listed in ClinicalTrials.gov as
NCT03328026. BriaCell is developing Bria-OTS™, an off-the-shelf personalized
immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments
are personalized to match the patient without the need for personalized
manufacturing. Bria-OTS™, which is expected to cover over 90% of the patient
population, is designed to produce a potent and selective immune response
against the cancer of each patient while eliminating the time, expense, and
complex manufacturing logistics associated with other personalized
immunotherapies. For more information, visit the company’s website at www.BriaCell.com
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment